OTIC - Otonomy, Inc.
| Previous Close | 2.3200 |
| Open | 2.2600 |
| Bid | 0.0000 x 1200 |
| Ask | 2.6600 x 900 |
| Day's Range | 2.2454 - 2.3200 |
| 52 Week Range | 1.5000 - 3.2000 |
| Volume | 26,974 |
| Avg. Volume | 35,139 |
| Market Cap | 70.721M |
| Beta (3Y Monthly) | 2.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6010 |
| Earnings Date | Mar 8, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.33 |
- Thomson Reuters StreetEvents
Edited Transcript of OTIC earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Otonomy Inc Earnings Call
- GlobeNewswire
Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Clinical-stage programs on track with results expected from three trials in 2020Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT.
- GlobeNewswire
Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update
SAN DIEGO, July 25, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- Simply Wall St.
Why Otonomy, Inc. (NASDAQ:OTIC) Is An Attractive Investment To Consider
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I...
- GlobeNewswire
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
SAN DIEGO, June 12, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- Thomson Reuters StreetEvents
Edited Transcript of OTIC earnings conference call or presentation 6-May-19 8:30pm GMT
Q1 2019 Otonomy Inc Earnings Call
- Zacks
Otonomy (OTIC) Reports Q1 Loss, Misses Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of 15.22% and -40.92%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Otonomy: 1Q Earnings Snapshot
The San Diego-based company said it had a loss of 39 cents per share. The biotechnology company posted revenue of $192,000 in the period. In the final minutes of trading on Monday, the company's shares ...
- GlobeNewswire
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX™ Phase 3 trial.
- ACCESSWIRE
Otonomy, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 6, 2019 / Otonomy, Inc. (NASDAQ: OTIC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 6, 2019 at 4:30 PM Eastern Time. ...
- PR Newswire
Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication
MAHWAH, N.J., May 2, 2019 /PRNewswire/ -- Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., today announced a co-promotion agreement with Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. Glenmark Therapeutics is dedicated to developing and commercializing a franchise of branded products for Glenmark Pharmaceuticals and is focused in the areas of respiratory and dermatology. Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), formerly GSP 301 Nasal Spray, is the company's leading respiratory pipeline asset and currently under review with the U.S. Food and Drug Administration (FDA) as a treatment for seasonal allergic rhinitis in patients 12 years and older.
- GlobeNewswire
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the signing of a co-promotion agreement with Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., which is dedicated to building and commercializing a franchise of branded products for Glenmark Pharmaceuticals focused in the areas of respiratory and dermatology. This agreement provides Glenmark Therapeutics with an exclusive right to promote OTIPRIO (ciprofloxacin otic suspension) to ear, nose and throat (ENT) physician offices in the United States and its territories for the treatment of acute otitis externa (AOE) in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.
- GlobeNewswire
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
SAN DIEGO, May 01, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- GlobeNewswire
Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2019 as well as provide a corporate update at 4:30 p.m. EDT on May 6, 2019. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 8076448. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.
- Simply Wall St.
Do Institutions Own Otonomy, Inc. (NASDAQ:OTIC) Shares?
If you want to know who really controls Otonomy, Inc. (NASDAQ:OTIC), then you'll have to look at the makeup of its share registry. Institutions often own shares in more established companies, while it's not unusual to see insiders...
- GlobeNewswire
Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-313, a sustained-exposure formulation of the NMDA receptor antagonist gacyclidine, in patients with tinnitus. The randomized, double-blind, placebo-controlled Phase 1/2 study will include an initial safety cohort followed by an exploratory efficacy study that will enroll approximately 50 patients with subjective tinnitus. "Tinnitus is a common problem affecting millions of people,” said Susan Marenda King, M.D., Neurotologist and Otologist at the Ear Medical Group in San Antonio, and Clinical Professor at the University of Texas Health Science Center.
- Zacks
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
- Zacks
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.
- Zacks
Will Otonomy Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Otonomy.
- Thomson Reuters StreetEvents
Edited Transcript of OTIC earnings conference call or presentation 4-Mar-19 9:30pm GMT
Q4 2018 Otonomy Inc Earnings Call
- Simply Wall St.
Those Who Purchased Otonomy Shares Three Years Ago Have A 84% Loss To Show For It
Otonomy, Inc. (NASDAQ:OTIC) shareholders should be happy to see the share price up 18% in the last month. But that is meagre solace in the face of the shocking declineRead More...
- GlobeNewswire
Otonomy to Participate in Two Upcoming Investor Conferences
SAN DIEGO, March 05, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- GlobeNewswire
Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019OTO-413 Phase.
- GlobeNewswire
Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update
SAN DIEGO, Feb. 25, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- GlobeNewswire
Analysis: Positioning to Benefit within Apache, A. O. Smith, Diamondback Energy, Maiden, Lands' End, and Otonomy — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
